All In Biotech

Drug Trial Radar · NCT00982007

Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA)

A Multi-center, Randomized, Active Controlled Study to Investigate the Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA)

Last checked: Nov 19, 2026Latest source record: Feb 20, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 997 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

997

Actual

Start

Sep 2009

Primary completion

Mar 2011

Study completion Aug 2011

Sponsor

Lead sponsor
American Regent, Inc.Industry
Sponsor type
Industry
First posted
Sep 22, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of this study is to demonstrate the efficacy and safety of an investigational intravenous (IV) iron, ferric carboxymaltose (FCM), compared to oral iron in subjects who have iron deficiency anemia (IDA) and have shown an unsatisfactory response to oral iron.

Conditions

  • Iron Deficiency Anemia

Interventions

  • Ferric Carboxymaltose (FCM)Drug

    A total maximum cumulative dose of 1500 mg administered on Days 0 and 7.

  • Ferrous Sulfate TabletsDrug

    325 mg Ferrous Sulfate tablets taken orally three times a day

  • IV Iron (standard of care)Drug

    IV standard of care (other IV iron) per the Investigator's discretion

  • Ferric Carboxymaltose (FCM)Drug

    A total maximum cumulative dose of 1500 mg administered on Days 0 and 7.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Increase From Baseline to the Highest Observed Hemoglobin Value Between Baseline and Day 35 or Time of Intervention for Patients Taking FCM as Compared to That for Patients Taking Ferrous Sulfate.Time frame: Day 35

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Luitpold Pharmaceuticals, Inc.

    Norristown, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.